

12th October 2023

## **Resignation of Director**

SomnoMed Limited advises Hilton Brett has tendered his resignation as a non-executive Director of the Company, effective 12<sup>th</sup> October 2023. Mr Brett has recently accepted a co-CEO role with Guzman y Gomez, of which he has been a non-executive director for many years.

SomnoMed thanks Mr Brett for his contribution to the Company, since his appointment as a non-executive director. Mr Brett joined the Board in 2020 and has been a member of the Audit and Risk Committee.

Mr Guy Russo, SomnoMed's Chairman said, "On behalf of the Board, I would like to thank Mr Brett for his valuable contribution to SomnoMed over the past three years."

Authorised for release to the ASX by Terry Flitcroft, Company Secretary

## **About SomnoMed**

SomnoMed is a public company providing diagnostic and treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent® becoming the state-of-the-art and clinically proven medical oral appliance therapy for obstructive sleep apnea. SomnoDent® is the most comfortable and effective design and treatment solution for more than 810,000 patients in 28 countries. For additional information, visit SomnoMed at <a href="http://www.somnomed.com.au">http://www.somnomed.com.au</a>